Loading
No description yet: the sentence for this tag has not been written. 12 records carry it: 5 key papers, 4 trials, 3 terms.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alliance A011202: axillary treatment after residual positive sentinel nodes NCT01901094 A011202 studies how to treat the axilla when sentinel nodes remain positive after chemotherapy. Both registry arms include radiation; this differs from the B-51 ypN0 question. | Breast cancer | none | local-treatment | ||
B-51: regional radiation after node-positive breast cancer becomes ypN0 Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ, Wolmark N. · The New England journal of medicine 2025 B-51 did not show a statistically significant recurrence benefit from regional irradiation in its selected post-chemotherapy ypN0 population. The confidence interval and surgery-specific comparison remain important. | Breast cancer | local-treatment | |||
BOOSTER: ablation during continuing immunotherapy for limited residual lung cancer Yang S, Liu X, Yu J, Chen X, Liu X, Zhao S, Jiang T, Sun H, Yang M, Wu F, Li A, Wang L, Gao G, Xu Y, Chen B, Ren S. · Signal transduction and targeted therapy 2025 This small randomised phase 2 trial found longer progression-free survival with ablation in selected lung cancer after an immunotherapy response. It did not test SBRT or establish one ablation method as universally best. | Non-small-cell lung cancer | local-treatment | |||
Completion surgery Completion surgery is a further operation after an earlier procedure and its findings. The tissue, reason and clinical setting determine the question; a pathology finding does not select one operation automatically. | Breast cancer, Triple-negative breast cancer | none | local-treatment | ||
CURB: adding SBRT for oligoprogressive breast or non-small-cell lung cancer Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN, CURB Study Group. · Lancet (London, England) 2024 CURB found longer progression-free survival overall with added SBRT, with different findings in its lung and breast cohorts. The small breast comparison did not show a statistically significant improvement. | Non-small-cell lung cancer, Breast cancer | local-treatment | |||
CURB: SBRT for oligoprogressive breast or non-small-cell lung cancer NCT03808662 CURB tested added SBRT for limited progression during systemic treatment. Its lung and breast subgroup findings should not be combined into one rule for every metastatic cancer. | Non-small-cell lung cancer, Breast cancer | local-treatment | |||
FUTURE-SUPER NCT04395989 FUTURE-SUPER tested a defined subtype-linked treatment strategy in advanced TNBC. The pooled phase 2 PFS comparison was positive; the current registry does not establish availability. | Triple-negative breast cancer | subtyping-strategy | |||
FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. · The Lancet. Oncology 2024 This randomised phase 2 trial found longer progression-free survival with a specified subtype-based combination strategy than with nab-paclitaxel alone, with more serious treatment-related adverse events. | Triple-negative breast cancer | randomised-phase-2 | |||
NRG-BR002: metastasis-directed ablation during first-line therapy for limited metastatic breast cancer Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, Matuszak MM, Milano MT, Jaskowiak NT, Jagsi R, Kuhn P, Lucci A, Meas S, Shishido SN, Mason J, Bazan JG, Nordal RA, Lee DY, Smith BD, Gabos Z, Ye JC, Kahn ST, Vallow LA, Zoberi I, Razaq W, Mishra MV, Lupinacci KM, Moughan J, Mamounas EP, White JR. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 NRG-BR002 did not show improved progression-free or overall survival from adding metastasis-directed ablation in its selected breast-cancer population. This result is distinct from local palliation. | Breast cancer | local-treatment | |||
NRG-BR002: metastasis-directed ablation in limited metastatic breast cancer NCT02364557 NRG-BR002 did not meet its progression endpoint for added metastasis-directed ablation in a selected breast-cancer population. The planned phase 3 portion did not proceed. | Breast cancer | local-treatment | |||
Regional nodal irradiation in breast cancer Regional nodal irradiation treats selected lymph-node regions. The exact fields, pretreatment findings and response after earlier therapy determine the clinical question. | Breast cancer, Triple-negative breast cancer | none | local-treatment | ||
TNBC molecular subtyping TNBC RNA subtyping compares gene-expression patterns under a named research classifier. Tissue mixture, method and version matter, and the result is separate from receptor tests or a treatment choice. | Triple-negative breast cancer | none | classification |